A Clinical Trial of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.

• ClinicalTrials.gov Identifier: NCT06298058
• Recruitment Status: Not yet recruiting
• First Posted: March 7, 2024
• Last Update Posted: March 7, 2024
• Sponsor: Shanghai Institute Of Biological Products
• Collaborator: Shanghai Pulmonary Hospital, Shanghai, China
• Information provided by (Responsible Party): Shanghai Institute Of Biological Products

Study Description

Brief Summary:

To evaluate the safety, tolerability, and pharmacokinetic characteristics of SIBP-A13 and determine the maximum tolerable dose (MTD) and phase II recommended dose (RP2D).

Condition or disease	Intervention/treatment	Phase
Advanced Solid Tumor	Drug: SIBP-A13 formulation for injection	Phase 1

Detailed Description:

This study is an open, multi-dose increasing single and multiple doses increasing, dose expanding, and indication expanding study to evaluate the safety, tolerability, pharmacokinetics, immunogenicity, preliminary anti-tumor efficacy, and explore potential biomarkers of SIBP-A13 in patients with advanced solid tumors.

This study is divided into three stages and is planned to be set up six dose groups, including 1, 2, 4, 5, 6, and 8 mg/kg. The first stage is the dose escalation stage, with a planned enrollment of 16-36 participants. The second stage is the dose expansion stage, where two doses are selected to enter the dose expansion phase. 6-9 late-stage solid tumor participants are enrolled in each dose group for dose expansion, and 12-18 participants are planned to be enrolled in the dose expansion phase. The third stage is the indication expansion stage, where phase II recommended dose (RP2D) is preliminarily determined based on the escalation and expansion of dosage in the early stage. Using RP2D for indication expansion, we plan to expand three indication cohorts, with at least 30 participants selected for each cohort.

Study Design

• Study Type: Interventional (Clinical Trial)
• Estimated Enrollment: 144 participants
• Allocation: N/A
• Intervention Model: Single Group Assignment
• Intervention Model Description: This study is an open, multi-dose increasing single and multiple dose study.
• Masking: None (Open Label)
• Primary Purpose: Treatment
• Official Title: A Phase I Clinical Study on the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SIBP-A13 Injection in the Treatment of Advanced Malignant Solid Tumor Patients.
• Estimated Study Start Date: March 12, 2024
• Estimated Primary Completion Date: April 30, 2026
• Estimated Study Completion Date: June 30, 2026

Arms and Interventions

Arm

Intervention/treatment

Experimental: SIBP-A13; SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion).

Drug: SIBP-A13 formulation for injection; SIBP-A13: injection; strength: 1, 2, 4, 5, 6 or 8 mg; dose escalation and the first group is 1mg (intravenous infusion). Starting from the lowest dose, when the former does not meet the termination criteria, then start the next dose group study until Maximum Tolerated Dose (MTD). The study adopts a "3+3" dose increasing design. Administration period: divided into single administration and multiple administration. Single dose administration: The participants are administered a single dose on the first day for a total of 21 days of observation, and complete the examinations and evaluations specify in the protocol. If dose-limiting toxicity (DLT) does not occur, the participant enters a multiple dosing period. Multiple administration: administration every 3 weeks.; Other Name: Her3-ADC

Outcome Measures

Primary Outcome Measures :

1. AE (Adverse Events) [ Time Frame: 28 days after the last dose ]
   That is adverse events, any adverse events that occurred to the participant during the study period.
2. SAE (Serious Adverse Events) [ Time Frame: 28 days after the last dose ]
   That is serious adverse events, any serious adverse events that occurred to the participant during the study period.
3. AUC (Area Under The Plasma Concentration Versus Time Curve) [ Time Frame: 18 weeks after the first dose ]
   It shows the degree to which a drug is absorbed and used in the body.
4. Cmax (Peak Plasma Concentration) [ Time Frame: 18 weeks after the first dose ]
   It shows the highest plasma concentration of a drug that can be achieved after administration.
5. Tmax (Peak Time) [ Time Frame: 18 weeks after the first dose ]
   That is peak time of drug action, it shows the time required to reach the maximum concentration on the participant plasma concentration curve after administration.
6. T ½ (Terminal elimination half-life) [ Time Frame: 18 weeks after the first dose ]
   It reflects how quickly the drug is eliminated from the body.
7. CL (Clearance Rate) [ Time Frame: 18 weeks after the first dose ]
   Apparent volume of drug distribution removed from the body per unit time.

Secondary Outcome Measures :

1. ORR (Objective Response Rate) [ Time Frame: 7 days after the last dose ]
   The proportion of participants whose tumor volume shrinks to a predetermined value and maintains the minimum time limit and is the sum of complete and partial responses.
2. DCR (Disease control rate) [ Time Frame: 7 days after the last dose ]
   In clinical trials, the percentage of participants with advanced or metastatic cancer who responded fully to cancer treatment, partially responded, and had stable disease.
3. PFS (Progression-free survival) [ Time Frame: 7 days after the last dose ]
   The time between the onset of randomization and the onset (of any aspect) of tumor progression or death (from any cause).
4. OS (overall survival) [ Time Frame: 7 days after the last dose ]
   From randomization to time of death due to any cause.

Eligibility Criteria

• Ages Eligible for Study: 18 Years to 75 Years (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

• Age range from 18 to 75 years old (including boundary values), regardless of gender.

• The clinical diagnosis of enrolled participants should meet the following criteria:

  1. Dose escalation and dose expansion stage: Patients with locally advanced or metastatic solid tumors confirmed by histology or cytology and judged by the researcher to be unable to benefit from available standard treatment, or intolerant.

  2. Indications expansion stage:

     • Queue 1: Non-small cell lung cancer (NSCLC) confirmed by histology or cytology, with disease progression and EGFR mutation during or after treatment with third generation TKI and platinum containing therapy.
     • Queue 2: Breast cancer (BC) confirmed as HER3 positive by histology or cytology after standard treatment failure.
     • Queue 3: Patients with recurrent/metastatic advanced HNSCC confirmed by histology or cytology, unsuitable for radical surgical resection, and standard treatment failure.
• At least one measurable lesion must be selected as the target lesion (according to RECIST v1.1 standard, computed tomography (CT) or magnetic resonance imaging (MRI)) (for lesions that have previously received radiotherapy, only with clear progression can they be selected as the target lesion).
• The patient has not previously used anti-HER3 antibodies or other HER3 targeted treatments (such as Deparezumab (HER3-DXd).
• Drugs that have not received any form of topoisomerase I inhibitor in the past, including antibody drug conjugates (ADCs) .
• ECOG score 0-1.
• Expected survival time ≥ 3 months.
• During the screening period, the main organ functions were basically normal (no medical support such as blood transfusion, granulocyte colony-stimulating factor (G-CSF), or other medical support was received within 14 days before the use of the investigational drug):

Blood routine: Absolute value of neutrophils (NE #) ≥ 1.5 × 10 9/L, platelet (PLT) count ≥ 90 × 10 9/L, hemoglobin (HGB) ≥ 90 g/L.

• Women of childbearing age during the screening period who have a negative blood pregnancy test and are capable of reproduction (including male participants) have no pregnancy plan and voluntarily take effective contraceptive measures during the trial period and within 6 months after the last dose.
• Voluntarily participate in this study and sign an informed consent form.

Exclusion Criteria:

• Participants with the following tumors:

  • The participant has had other malignant tumors that have not been cured within the past 5 years (excluding malignant tumors that have been clearly cured, such as thyroid cancer, cured basal cell carcinoma of the skin, and cervical carcinoma in situ).
  • The participant has untreated imaging confirmed central nervous system metastasis.
  • Meningeal metastases.
  • Patients with brain metastases who have received systematic or curative brain metastasis treatment (radiotherapy or surgery) in the past, have been confirmed stable by imaging for at least 4 weeks, and have stopped systemic hormone, antiepileptic, convulsive drugs, and other treatments for more than 2 weeks without clinical symptoms can be enrolled.

• Participants with a history of previous treatment or surgery, or those who received the following anti-tumor treatments during the planned trial period:

  • Patients who accepted the instructions clearly containing traditional Chinese patent medicines and simple preparations with anti-tumor effect within 2 weeks before the first administration;
  • Patients undergoing adjuvant therapy within 6 months after surgery;
  • Patients who have not recovered from the toxicity of the previous anti-tumor treatment to normal or ≤ level 1 (excluding hair loss);
  • Patients who have undergone major surgery, radiation therapy, biological therapy, or chemotherapy within 4 weeks prior to their first administration, or who have received systemic treatment such as unhealed surgical wounds, ulcers or fractures, or other clinical trial drugs.
  • Patients who plan to receive any other anti-tumor treatment (chemotherapy, radiation therapy, immunotherapy, cytokine therapy other than erythropoietin) during the trial period should be excluded (excluding testosterone lowering therapy for prostate cancer patients).
  • The dose (prednisone>10 mg/d or equivalent) at which immunosuppressive effects are achieved by receiving immunosuppressive agents or systemic corticosteroids within one week prior to the use of the investigational drug.

• Participants with a history of previous illnesses or laboratory tests that show the following abnormalities:

  • Individuals with abnormal coagulation function and a tendency to bleed, or who are undergoing thrombolysis or anticoagulation treatment or have lost blood or donated more than 400 mL within 2 months prior to administration.
  • Have a history of immunodeficiency, including HIV testing positive, or other acquired or congenital immunodeficiency diseases, or a history of organ transplantation.
  • Have a clear history of neurological or psychiatric disorders, including epilepsy or dementia.
• Screening period for syphilis spiral antibody positive individuals; Individuals with active HBV and HCV infections; Except those with stable hepatitis B (DNA titer below the lower detection limit) and cured hepatitis C (HCV RNA test negative) after drug treatment.
• Patients with ascites, pleural effusion, and pericardial effusion accompanied by clinical symptoms during the screening period who require drainage, or those who have undergone serous cavity drainage within 4 weeks before the first administration.

• The screening period is accompanied by severe, progressive, or uncontrollable diseases, and the researcher's evaluation determines that the participation of the participants in the study will increase the risk. Including but not limited to:

  • Cerebrovascular accidents or transient ischemic attacks (within the first 6 months of screening); Suffering from heart disease judged by the researcher as unsuitable for participation in this trial, with a severity of cardiac or renal dysfunction ≥ Level II.

• According to the researcher's judgment, there are accompanying diseases that seriously endanger patient safety or affect patient completion of the study.

  1. Hypertension that cannot be controlled clinically.
  2. Diabetes with poor drug control.
  3. Clinically significant thyroid diseases judged by researchers as unsuitable for inclusion.
  4. Serious infections that occurred within 4 weeks prior to initiating research treatment.
• Individuals with a history of severe allergies to protein products, Chinese hamster ovary cell (CHO) cell products, and other recombinant human or humanized antibodies, or to the components of the investigational drug.
• Pregnant and lactating women.
• Patients deemed unsuitable for inclusion by researchers.

Contacts and Locations

Contacts

Contact: Dandan Chen, Master; 86-021-62800991; ddchen.sh@sinopharm.com

Contact: Yanni Zhou, Master; 86-021-62800991; zhouyanni3@sinopharm.com

Sponsors and Collaborators

Shanghai Institute Of Biological Products

Shanghai Pulmonary Hospital, Shanghai, China

Investigators

• Principal Investigator: Caicun Zhou, Doctor; Shanghai Pulmonary Hospital, Shanghai, China

More Information

• Responsible Party: Shanghai Institute Of Biological Products
• ClinicalTrials.gov Identifier: NCT06298058
• Other Study ID Numbers: SIBP-A13-I
• First Posted: March 7, 2024
• Last Update Posted: March 7, 2024
• Last Verified: February 2024

Individual Participant Data (IPD) Sharing Statement:

• Plan to Share IPD: No

• Studies a U.S. FDA-regulated Drug Product: No
• Studies a U.S. FDA-regulated Device Product: No

Keywords provided by Shanghai Institute Of Biological Products:

Advanced solid tumor; Her3-ADC; Safety; Efficacy; Pharmacokinetics

Additional relevant MeSH terms:

Neoplasms